Carbamylated Low-Density Lipoprotein: Nontraditional Risk Factor for Cardiovascular Events in Patients With Chronic Kidney Disease

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 134-138

  Apostolov, Eugene O ^a   Basnakian, Alexei G ^a   Ok, Ercan ^b   Shah, Sudhir V ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMYL LDL; CARBAMYL-LDL; LOW DENSITY LIPOPROTEIN;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL; RENAL DIALYSIS; RISK FACTORS;

EID: 84855168560     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.023     Document Type: Article

References (16)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
2. Kalantar-Zadeh K., Block G., Humphreys M.H., Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63:793-808.
3. Keith D.S., Nichols G.A., Gullion C.M., Betz Brown J., Smith D.H. Longitudinal follow-up and outcomes amonga population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
4. Wanner C., Krane V., Winfried M., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
5. Fellström B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
6. Basnakian A.G., Shah S.V., Ok E., Altunel E., Apostolov E.O. Carbamylated LDL. Adv Clin Chem 2010, 51:25-52.
7. Wang Z., Nicholls S.J., Rodriguez E.R., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. NatMed 2007, 13:1176-1184.
8. Ok E., Basnakian A.G., Apostolov E.O., Shah S.V. Carbamylated low-density lipoprotein induces death of endothelial cells:a link to atherosclerosis in patients with kidney disease. Kidney Int 2005, 68:173-178.
9. Apostolov E.O., Basnakian A.G., Yin X., Ok E., Shah S.V. Modified LDLs induce proliferation-mediated death of human vascular endothelial cells through the MAPK pathway. Am J Physiol Heart Circ Physiol 2006, 292:H1836-H1846.
10. Apostolov E.O., Shah S.V., Ok E., Basnakian A.G. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-2. Arterioscler Thromb Vasc Biol 2007, 68:826-832.
11. Asci G., Basci A., Shah S.V., et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology (Carlton) 2008, 13:480-486.
12. Apostolov E.O., Shah S.V., Ray D., Basnakian A.G. Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol 2009, 29:1622-1630.
13. Apostolov E.O., Ray D., Alobuia W.M., et al. Endonuclease Gmediates endothelial cell death induced by carbamylated LDL. Am J Physiol Heart Circ Physiol 2011, 300:H1997-H2004.
14. Carracedo J., Merino A., Briceño C., et al. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J 2011, 25:1314-1322.
15. Apostolov E.O., Ray D., Savenka A.V., Shah S.V., Basnakian A.G. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010, 21:1852-1857.
16. Apostolov E.O., Shah S.V., Ok E., Basnakian A.G. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem 2005, 51:719-728.